Endpoints
MorphoSys AG: Primary Endpoint of L-MIND, a Combination Study of Tafasitamab (MOR208) and Lenalidomide, Has Been Met, Confirming Previously Published Activity
MorphoSys
PR-M05-19-NI-065May 22, 2019
Enpoint
Lilly's CYRAMZA® Phase 3 RELAY Trial Met Primary Endpoint in First-Line Treatment of Patients with Metastatic EGFR-Mutated Non-Small Cell Lung Cancer
Eli Lilly and Company
PR-M03-19-NI-039Mar 14, 2019